<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701948</url>
  </required_header>
  <id_info>
    <org_study_id>4108</org_study_id>
    <nct_id>NCT00701948</nct_id>
  </id_info>
  <brief_title>New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn</brief_title>
  <acronym>NOSODIAG</acronym>
  <official_title>Interest of New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate new dosage of inflammatory markers or new inflammatory markers
      for the diagnosis of nosocomial bacterial infection. We made the hypothesis that these new
      dosages or new inflammatory markers could be more useful than dosage of inflammatory markers
      already used in clinical practice (especially the use of a combination of interleukins (6 or
      8) and C-reactive protein for the management of newborns with a clinical suspicion of
      nosocomial bacterial infection and especially could allow to avoid excessive treatment with
      antibiotics
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of new dosage of inflammatory markers or new inflammatory markers for the diagnosis of nosocomial bacterial infection.</measure>
    <time_frame>48 hours and at 72 hours</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">240</enrollment>
  <condition>Nosocomial Infection</condition>
  <arm_group>
    <arm_group_label>A-1</arm_group_label>
    <description>Proven nosocomial bacterial infection (NBI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-2</arm_group_label>
    <description>Possible NBI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-1</arm_group_label>
    <description>Absence of NBI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-2</arm_group_label>
    <description>Probable absence of NBI</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newborn hospitalized in neonatal intensive care unit with a clinical suspicion of
        nosocomial bacterial infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborns &gt; 72 hours of life hospitalized in neonatal intensive or intermediate care
             unit presenting a clinical suspicion of NBI

        Exclusion Criteria:

          -  Early post-operative period ( surgery of less than 48 hours)

          -  Multiple malformations

          -  Newborn already included in the study for a previous septic events

          -  Newborn treated with antibiotics in the last 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Kuhn, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Pédiatrie 2 - Hôpital d'Enfants CHU de Dijon; 10 - bld Maréchal de Lattre de Tassigny</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pédiatrie 2 - Hôpital de Hautepierre; 1 - Avenue Molière</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Late onset neonatal sepsis</keyword>
  <keyword>Nosocomial bacterial infection</keyword>
  <keyword>Inflammatory markers</keyword>
  <keyword>multiplex dosage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

